Cargando…

Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS

BACKGROUND: Left ventricular assist devices (LVADs) improve outcomes in patients with end‐stage heart failure and are increasingly implanted for destination therapy. We describe dynamic estimates of event‐free survival with conditional survival probabilities in a destination therapy LVAD population....

Descripción completa

Detalles Bibliográficos
Autores principales: Michelis, Katherine C., Zhong, Lin, Peltz, Matthias, Pandey, Ambarish, Tang, W. H. Wilson, Rohatgi, Anand, Young, James B., Drazner, Mark H., Grodin, Justin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660737/
https://www.ncbi.nlm.nih.gov/pubmed/32648531
http://dx.doi.org/10.1161/JAHA.119.016203
_version_ 1783609069943128064
author Michelis, Katherine C.
Zhong, Lin
Peltz, Matthias
Pandey, Ambarish
Tang, W. H. Wilson
Rohatgi, Anand
Young, James B.
Drazner, Mark H.
Grodin, Justin L.
author_facet Michelis, Katherine C.
Zhong, Lin
Peltz, Matthias
Pandey, Ambarish
Tang, W. H. Wilson
Rohatgi, Anand
Young, James B.
Drazner, Mark H.
Grodin, Justin L.
author_sort Michelis, Katherine C.
collection PubMed
description BACKGROUND: Left ventricular assist devices (LVADs) improve outcomes in patients with end‐stage heart failure and are increasingly implanted for destination therapy. We describe dynamic estimates of event‐free survival with conditional survival probabilities in a destination therapy LVAD population. METHODS AND RESULTS: We studied 8245 adult patients in INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) implanted with a continuous‐flow destination therapy LVAD. The composite primary end point was death, device exchange or removal, or heart transplantation. Conditional survival probabilities were calculated and stratified by implantation characteristics and nonfatal adverse events experienced within the first year after implant. Probabilities of surviving an additional 1 to 3 years were numerically higher after longer prior event‐free survival. INTERMACS profile 1, extracorporeal membrane oxygenation support, prior or concomitant surgery, and dialysis within 48 hours of implantation were associated with significantly lower event‐free survival in the first year but did not impact event‐free survival beyond then. For patients who experienced a nonfatal adverse event within the first year, subsequent 1‐year conditional survival was lower than in the absence of that event for stroke (65% [95% CI, 57%–73%] versus 75% [95% CI, 73%–77%]; P<0.001), device‐related infection (64% [95% CI 57%–71%] versus 76% [95% CI, 74%–78%]; P<0.001), and pump thrombosis or malfunction (64% [95% CI, 57%–70%] versus 76% [95% CI, 74%–78%]; P<0.001). CONCLUSIONS: Conditional survival in patients with destination therapy LVADs improves over time, even for patients with unfavorable implantation characteristics. However, LVAD‐related complications including stroke, device‐related infection, and pump thrombosis or malfunction have an enduring negative influence on dynamic estimates of long‐term prognosis.
format Online
Article
Text
id pubmed-7660737
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76607372020-11-17 Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS Michelis, Katherine C. Zhong, Lin Peltz, Matthias Pandey, Ambarish Tang, W. H. Wilson Rohatgi, Anand Young, James B. Drazner, Mark H. Grodin, Justin L. J Am Heart Assoc Original Research BACKGROUND: Left ventricular assist devices (LVADs) improve outcomes in patients with end‐stage heart failure and are increasingly implanted for destination therapy. We describe dynamic estimates of event‐free survival with conditional survival probabilities in a destination therapy LVAD population. METHODS AND RESULTS: We studied 8245 adult patients in INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) implanted with a continuous‐flow destination therapy LVAD. The composite primary end point was death, device exchange or removal, or heart transplantation. Conditional survival probabilities were calculated and stratified by implantation characteristics and nonfatal adverse events experienced within the first year after implant. Probabilities of surviving an additional 1 to 3 years were numerically higher after longer prior event‐free survival. INTERMACS profile 1, extracorporeal membrane oxygenation support, prior or concomitant surgery, and dialysis within 48 hours of implantation were associated with significantly lower event‐free survival in the first year but did not impact event‐free survival beyond then. For patients who experienced a nonfatal adverse event within the first year, subsequent 1‐year conditional survival was lower than in the absence of that event for stroke (65% [95% CI, 57%–73%] versus 75% [95% CI, 73%–77%]; P<0.001), device‐related infection (64% [95% CI 57%–71%] versus 76% [95% CI, 74%–78%]; P<0.001), and pump thrombosis or malfunction (64% [95% CI, 57%–70%] versus 76% [95% CI, 74%–78%]; P<0.001). CONCLUSIONS: Conditional survival in patients with destination therapy LVADs improves over time, even for patients with unfavorable implantation characteristics. However, LVAD‐related complications including stroke, device‐related infection, and pump thrombosis or malfunction have an enduring negative influence on dynamic estimates of long‐term prognosis. John Wiley and Sons Inc. 2020-07-10 /pmc/articles/PMC7660737/ /pubmed/32648531 http://dx.doi.org/10.1161/JAHA.119.016203 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Michelis, Katherine C.
Zhong, Lin
Peltz, Matthias
Pandey, Ambarish
Tang, W. H. Wilson
Rohatgi, Anand
Young, James B.
Drazner, Mark H.
Grodin, Justin L.
Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS
title Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS
title_full Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS
title_fullStr Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS
title_full_unstemmed Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS
title_short Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS
title_sort dynamic forecasts of survival for patients living with destination left ventricular assist devices: insights from intermacs
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660737/
https://www.ncbi.nlm.nih.gov/pubmed/32648531
http://dx.doi.org/10.1161/JAHA.119.016203
work_keys_str_mv AT micheliskatherinec dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs
AT zhonglin dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs
AT peltzmatthias dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs
AT pandeyambarish dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs
AT tangwhwilson dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs
AT rohatgianand dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs
AT youngjamesb dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs
AT draznermarkh dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs
AT grodinjustinl dynamicforecastsofsurvivalforpatientslivingwithdestinationleftventricularassistdevicesinsightsfromintermacs